Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7-10% of acute lymphoblastic leukemia (ALL) and 5-6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL-AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL -the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation. Oncogene (2003 Oncogene ( ) 22, 1418 Oncogene ( -1424 Oncogene ( . doi:10.1038 Keywords: t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukemia Translocations within the 11q23 chromosomal band are among the most common leukemia-specific abnormalities and produce MLL fusions with loci on more than 40 other chromosomal bands (Rowley, 1998; Ayton and Cleary, 2001 ). The mixed lineage leukemia gene (MLL) (Ziemin-van der Poel et al., 1991) is also known as acute lymphoblastic leukemia gene 1 (ALL-1) (Gu et al., 1992) , human trithorax gene Htrx (Djabali et al., 1992) or HRX (Tkachuk et al., 1992) , and occurs in several alternatively spliced forms: a commonly observed form contains a 11 919-bp ORF with 37 exons that encode a 3972-amino-acid (aa) protein, while a less abundant form contains an ORF of 12 018 bp (additional exon 2, giving a total of 38 exons) that encodes a 4005-aa protein (Nilson et al., 1996) . Chromosomal translocations involving MLL cluster within an 8.3-kb BamHI fragment, encompassing exons 8-14 (the numbering of MLL exons throughout this manuscript is according to Nilson et al., 1996) .
To date, more than 30 MLL fusion partners have been molecularly identified. These translocations generate fusions in which only the der(11)-encoded mRNA is consistently detected; the chimeric proteins consist of the N-terminus of MLL fused in-frame to variable segments encoded by the partner genes. This N-terminal MLL protein segment contains three AT hook motifs that mediate binding to the minor groove of DNA, an 'MT' motif with high similarity to the noncatalytic domains of human DNA methyltransferases, and part of a putative transcriptional repression domain that partially overlaps the MT motif (Zeleznik-Le et al., 1994) . Other more C-terminal MLL domains, including two central zinc fingers known as plant homeodomain (PHD) fingers, a transcriptional activation domain, and a region with high homology to the Drosophila trithorax, enhancer of zeste and Su(var)3-9 genes are not incorporated into the der(11)-encoded fusion products (Ayton and Cleary, 2001) .
Although rare, a recurrent translocation, t(11;15) (q23;q14), has been reported both in patients with ALL or acute myeloid leukemia (AML) (Harrison et al., 1998) . In two cases of AML-M4, the translocation was associated with an abnormality of chromosome 3, and Southern analysis confirmed a rearrangement of MLL in one of them (Archimbaud et al., 1998) . The translocation was found in association with other chromosome abnormalities in two cases of ALL (Groupe Francais de Cytogenetique Hematologique, 1993; Raimondi et al., 1991) , one of AML-M1 (Herna´ndez et al., 1995) and two of AML-M2 (Herna´ndez et al., 1995) .
A novel MLL partner gene on chromosome 15, AF15q14, was cloned recently by Hayette et al. (2000) from a 48-year-old male with AML-M4 containing t(11;15). Prior to publication of the study by Hayette et al., our group had described the cloning of the chimeric genomic fragment produced by t(11;15) in a 3-year-old boy with de novo T-ALL and had reported our initial characterization of the transcriptional unit from chromosome 15 altered by this rearrangement, which we named AF15 (Kuefer et al., 1997) . Sequence comparison of AF15 with the AF15q14 gene cloned by Hayette et al. (2000) confirmed that they are one and the same gene, which we will also refer to subsequently as AF15q14 to avoid confusion. Despite the identity of AF15q14 as reported by Hayette et al. and the gene described here, we find a number of significant differences, discussed below in detail. Further, we compare our findings also with those reported in the companion manuscript by Chinwalla and colleagues (2003) , which describes yet other molecular consequences occurring due to the t(11;15).
Cytogenetic studies at diagnosis confirmed the presence of t(11;15)(q23;q14) in our patient's leukemia, and Southern hybridization using a 740-bp BamHI MLL cDNA fragment that spans the breakpoint cluster region of MLL confirmed involvement of the gene (Figure 1a and b). To characterize the chromosome 15 locus fused , which is located in AF15q14 exon 11 (see Figure 2b) to MLL, we prepared a subgenomic l phage library using BamHI-digested leukemia DNA and screened this library with the 740-bp BamHI MLL probe to isolate an B4.5-kb BamHI rearranged fragment. Sequence analysis indicated that B1.5 kb of this genomic fragment was derived from chromosome 11 and that MLL exons 8 and 9 were on this segment, indicating that the MLL breakpoint occurred within intron 9 and that the B4.5-kb BamHI fragment was derived from the der(11). According to the genomic sequence of the MLL major breakpoint region (GenBank Acc. Nos. X83604 and CAA93625) (Nilson et al., 1996) , exon 9 extends from nucleotides (nts) 829-902, intron 9 extends from nts 903-2580, and the genomic MLL breakpoint in our case occurred after nt 2101. The sequence then matched the AF15q14 cDNA identified by our group (vide infra) starting at nt 1648 (numbering based on GenBank Acc. No. AF173994) (Figure 1c ), and the AF15q14 breakpoint was thus found to fall within exon 11 of the gene (vide infra). A 2.9-kb SmaI/BamHI subfragment, representing most of the non-MLL portion of the B4.5-kb BamHI chimeric clone, was hybridized to a human monochromosome somatic cell hybrid DNA Southern blot, confirming its location to chromosome 15 (not shown).
To determine whether the 2.9-kb SmaI/BamHI chromosome 15 fragment contained transcribed sequences, we used the clone to probe Northern blots prepared from normal fetal and adult human tissues. An B9.5-kb message, together with a much less abundant B7.5-kb transcript, was identified in several tissues (Figure 2a ). In the adult, transcripts were abundant in testis and thymus, with very low levels in placenta; expression in the fetus was by far greatest in, although not restricted to, the liver.
For further characterization of this chromosome 15 gene (which we refer to by consensus as AF15q14, as noted above), human testis and thymus cDNA libraries were screened using the 2.9-kb SmaI/BamHI chromosome 15 genomic fragment as a probe. The two largest clones isolated (both from testis library no. HL3024b, Clontech, Palo Alto, CA, USA), together with the 2.9-kb genomic fragment, were sequenced in their entirety. The sequences in these three clones contained a long ORF of 4101 nts that lacked both initiation and termination codons. Using 5 0 RACE, we identified the beginning of the coding sequence of AF15q14. By PCRbased screening of a human thymus cDNA library (Genome Systems, Inc., St Louis, MO, USA) with primers homologous to the 3 0 end of the previously obtained sequence, we identified a complete AF15q14 3 0 coding sequence. Our AF15q14 cDNA sequence (GenBank Accession number AF173994) consists of 7542 nts and contains an ORF encoding a 2342-aa protein with a predicted mass of 265.3 kDa. The 5 0 untranslated region (UTR) of our AF15q14 cDNA is 390 nts and the 3 0 UTR is 123 nts. The 3 0 UTR sequence in our cDNA is likely incomplete given that it lacks both a consensus polyadenylation signal and a poly(A) tract. Since the AF15q14 transcripts we identified on Northern analysis are B7.5 and 9.5 kb, the 7542-nt cDNA that we cloned presumably represents the smaller of these transcripts, the larger message perhaps containing additional 5 0 or 3 0 untranslated sequences yet to be identified. Indeed, UCSC Genome Browser (http://www.genome.ucsc.edu) and AceView (http://www.ncbi.nih.gov/AceView) predictions of the AF15q14 genomic structure suggest the existence of possible additional exons downstream of the most 3 0 exon (exon 27) identified using our cDNA sequence (vide infra). It is important to note that Hayette et al., in addition to their originally reported cDNA, have recently deposited an AF15q14 cDNA sequence (GenBank Accession number AF461041) that is essentially identical to the cDNA that we describe here, with the exception of the absence of a single 78-nt exon (exon 7, vide infra) located near the 5 0 end of our coding sequence.
Comparison of our AF15q14 cDNA sequence with the genomic locus (GenBank Accession number AC022405) revealed the gene to consist of at least 27 exons (rather than the 10 exons reported originally by Hayette et al., 2000) and to span a minimum of 68.3 kb (Figure 2b ). The initiator ATG is located in exon 2 and the stop codon is present in exon 27. Our AF15q14 sequence contains an additional exon (exon 7 in Figure 2b ) that is absent in the genomic and cDNA sequences reported by Hayette et al. (2000) , and in an additional recently described AF15q14 cDNA sequence (Takimoto et al., 2002) . The coding sequences within this additional exon do not change the AF15q14 ORF. Further, our AF15q14 cDNA sequence contains a longer 5 0 UTR, and encodes for a larger protein that contains 2342 aa in contrast to the AF15q14 protein of 1833 aa originally reported by Hayette et al. (2000) . As noted above, the genomic breakpoint in our case occurred in AF15q14 exon 11 (which corresponds to exon 10 by the numbering of Hayette et al., 2000) . The respective locations of the AF15q14 genomic breakpoints in our patient and in the cases reported by Hayette et al. (2000) and in the accompanying article by Chinwalla et al. (2003) are shown in Figure 2b .
Following our identification of the AF15q14 cDNA sequence, we performed RT-PCR using total RNA from our patient's leukemic marrow to clone the chimeric cDNA formed by t(11;15). We used an MLL exon 8 primer and two different AF15q14 primers, AF15q14 6104B and AF15q14 7421B, which are located in exons 14 and 27 of the normal AF15q14 cDNA, respectively (see Figure 2b) , for first-round PCR amplifications. A second round of PCRs was then performed using nested AF15q14 primers -a 500-bp amplicon was obtained with AF15q14 nested primer 6084B (using the first PCR product obtained with primer 6104B as the template) and a 1.8-kb product was amplified with nested primer 7366B (using the initial product obtained with primer 7421B as the template). Sequencing revealed the breakpoint in both of these fragments to be the same: fusion of MLL exon 9 to AF15q14 exon 12. This chimeric cDNA maintains the AF15q14 ORF, thus encoding a fusion protein that contains the N-terminus of MLL up to K1362 fused to the entire C-terminus of AF15q14 starting at residue I1819 (Figure 3a) . The entire coding sequence of this MLL-AF15q14 fusion is 5658 nts, generating a predicted 1886-aa chimeric protein with a mass of 208 kDa (Figure 3b, lower schematic) .
Here we describe the cloning of t(11;15)(q23;q14), a rare but recurrent rearrangement in both ALL and AML (Harrison et al., 1998) , and the characterization of AF15q14. Similar to the majority of MLL breakpoints in de novo leukemias, the t(11;15) break maps to the first half of the 8.3-kb BamHI breakpoint cluster region between two scaffold-associated regions (Broeker et al., 1996) , suggesting that the breakpoint distribution may be determined in part by the chromatin structure.
The MLL-AF15q14 genomic breakpoint in our patient occurs at AF15q14 nt 1648, which falls within exon 11 of the gene (Figure 2b ). In the MLL-AF15q14 + RNAs from various human tissues were hybridized with a 2.9-kb SmaI/BamHI exon-containing genomic AF15q14 probe located just 3 0 of the MLL-AF15q14 breakpoint junction. The two normal AF15q14 messages of B9.5 and 7.5 kb are indicated. (b) Genomic structure of AF15q14. Numbers under each exon represent the exon sizes. Introns are represented by dotted lines and are not drawn to scale. Primers 6104B and 7421B used in RT-PCR are indicated, with an arrow pointing in the direction of primer extension. Breakpoints of three patients are shown: BP 1, exonic break described in this report; BP 2, intronic break described by Chinwalla et al. (2003) ; BP 3, exonic break reported by Hayette et al. (2000) . The chimeric MLL-AF15q14 cDNAs reported here and by Chinwalla et al. are identical (both having their stop codon in exon 27 of the corresponding normal AF15q14 gene), with AF15q14 exon 11 sequences being excluded from our patient's fusion. The initial 11 exons shown here correspond to the 10 exons reported to comprise the entire normal AF15q14 locus by Hayette et al. (2000) plus the 78-nt exon 7, which was not previously identified; exons 12-27 were also not previously described. All newly identified exons are indicated by gray shading. Only those AF15q14 exons containing sequences present in the 7542-bp cDNA reported here are illustrated; exon 27 contains additional 3 0 sequences not present in our cDNA (the predicted size based on genome sequence analysis using UCSC Genome Browser (http://www.genome.ucsc.edu) being 610 bp). Both UCSC Genome Browser and AceView (http:// www.ncbi.nih.gov/AceView) predictions suggest the possible existence of additional exons downstream of exon 27 as well fusion cDNA transcript, MLL exon 9 is fused to AF15q14 exon 12 beginning with nt 5845, the first nt of this AF15q14 exon. This in-frame fusion adds 524 aa from AF15q14 to the MLL-AF15q14 protein (with the stop codon being the same as that we have identified for normal AF15q14). From the genomic breakpoint at AF15q14 nt 1648 to the cDNA fusion junction at AF15q14 nt 5845, the exon 11 sequences are excluded from the chimeric cDNA. Although a fusion of MLL exon 9 to AF15q14 beginning at nt 1648 would maintain the AF15q14 ORF, the absence of AF15q14 exon 11 sequences presumably occurs due to the lack of a functional splice acceptor site (Senapathy et al., 1990) at the MLL-AF15q14 genomic junction (Figure 1c ).
In the case described by Hayette et al. (2000) , an intraexonic break within MLL exon 11 (numbering according to Nilson et al. (1996) ; corresponding to exon 8 with the numbering used by Hayette et al., 2000) occurs, with fusion to AF15q14 at nt 5712 (numbering based on GenBank Accession number AF173994). The genomic break at AF15q14 nt 5712 in this case occurs in the same exon (exon 11 by our numbering; exon 10 by the numbering of Hayette et al., 2000) as our case, but at different ends of the exon (see Figure 2b) . Hayette et al. (2000) predicted an in-frame fusion of MLL to AF15q14, starting immediately at AF15q14 nt 5712 but incorporating only 85 aa from AF15q14. Our examination of the AF15q14 genomic locus suggests that the MLL-AF15q14 sequence reported by Hayette et al. (2000) following the AF15q14 breakpoint in their case appears to be partially intronic (based on our comparison of the genomic locus with the cDNA we report here), although these sequences could well represent an alternatively spliced exon unique to the cDNA that they characterized. Specifically, the C-terminal 41 aa in both the normal AF15q14 and the MLL-AF15q14 fusion proteins as reported by Hayette et al. (2000) may represent an alternative AF15q14 splice form, with these C-terminal residues being derived from sequences that we include as part of our intron 11 (our numbering for AF15q14; see Figure 2b ). In support of this possibility, it is interesting to note that the AF15q14 cDNA recently reported by Takimoto et al. (2002) seems to represent an additional putative form of AF15q14 that is shortened (similarly to the original form reported by Hayette et al., 2000) and of different aa sequence at its C-terminus due apparently to alternative splicing at the extreme 3 0 end of the exon 11 sequences we report here. These data suggest that several different splice forms of AF15q14 may normally exist.
Unfortunately, the true composition of the MLLAF15q14 cDNA in the case reported by Hayette et al. (2000) cannot be confirmed, as no leukemia cell RNA was available to these investigators, therefore precluding characterization of their chimeric cDNA (R Rimokh, Unite INSERM U453, Lyon, France, personal communication). However, the fusion protein postulated by Hayette et al. (2000) would differ substantially from the Hayette et al. (2000) and the lower illustrating the fusion discussed here and by Chinwalla et al. (2003) . As noted in the text, the existence of the shorter chimera reported by Hayette et al. (2000) has not yet been confirmed because RNA was unavailable from their case for analysis. MT, methyltransferase homology domain; BP, fusion breakpoint; BP-NLS, bipartite nuclear localization signal; CC, coiled-coil domain MLL-AF15q14 fusion proteins expressed in our patient and that described by Chinwalla and co-workers (2003) , which are identical. For example, the bipartite nuclear localization signal (BP-NLS) of AF15q14 would be present uniquely in the fusion postulated by Hayette et al. (2000) , whereas a coiled-coil domain that we describe in the C-terminus of the protein would be present only in the fusion that we and Chinwalla et al. (2003) report (Figure 3b ). Whether these apparent differences in the fusions generated by the t(11;15) could impact the phenotype of MLL-AF15q14-expressing leukemias will require analysis of additional translocation-positive cases, as well as examination of the functional characteristics of the chimeric proteins.
Neither sequence nor functional similarities among all of the known MLL fusion partners have yet been identified. However, studies of the leukemogenic potential of MLL gene fusions suggest that the partner genes do serve essential roles, MLL truncation alone being insufficient to result in the development of malignancy (for example, see Corral et al., 1996; Lavau et al., 1997) . Our database searches using the deduced AF15q14 sequence identified the aforementioned BP-NLS (residues 1787-1803 in the protein described here; GenBank Accession number AF173994) and a previously undescribed C-terminal coiled-coil domain (residues 2018-2133), but no regions of significant homology to previously identified MLL fusion partners. AF15q14, however, appears identical to the so-called S6 A-8 mRNA (GenBank Accession number U52052) expressed in chromosome 6-suppressed melanoma cells (Ray et al., 1996) . S6 A-8 was identified due to its upregulation during tumor suppression of melanoma cells following experimental introduction into them of a normal human chromosome 6 (in studies designed to identify the effects of putative tumor suppressor genes deleted from chromosome 6q during human melanoma development and progression). Another gene found to be upregulated was SCF (stem cell factor, c-kit ligand), a factor critical for normal hematopoiesis, neural crest development and melanocyte differentiation.
The disruption of AF15q14 by translocation, with ensuing functional loss of one allele after fusion to MLL, may serve to interfere with a yet-to-be defined role for the gene in the regulation of normal hematopoiesis. Indeed, the expression of AF15q14 in fetal liver and thymus suggests the gene could normally function in hematopoietic development. The MLL-AF15q14 fusion protein might also dominantly suppress a normal function of AF15q14 as a tumor suppressor, thereby contributing to leukemogenesis. For example, loss of function has been suggested for the adenoviral E1A-associated protein p300, a functional homologue of the transcriptional coactivator CBP (Lundblad et al., 1995) , which may be unable to regulate the cell cycle and cellular differentiation after its fusion to MLL in acute myeloid leukemias with t(11;22)(q23;q13) (Ida et al., 1997) . Additionally, chimeric MLL-AF15q14 transcripts could lead to a gain of AF15q14 function and an induction of transforming activity. As an example, MLL-ENL was shown to require the transcriptional transactivating function of ENL, together with the DNA-binding motifs of MLL, for its oncogenic capability (Slany et al., 1998) . A recent report describing the more frequent expression of AF15q14 in poorly differentiated as compared to well or moderately differentiated lung cancers in patients who smoke is potentially consistent with an active role for deregulation of the gene in malignant transformation (Takimoto et al., 2002) . It should be emphasized that all of these putative roles for AF15q14 in oncogenesis are at present speculative and will require functional and genetic data for validation, of course.
Analysis of other leukemias containing t(11;15) (q23;q14) (see Chinwalla et al., 2003) shows that at least one additional 15q14 locus, MPFYVE, can be involved in some of these translocations. Functional studies of MLL-AF15q14, expressed alone or together with the MLL-MPFYVE fusion, should clarify the oncogenic mechanisms utilized by these novel MLL chimeric proteins.
DNA sequences
The AF15q14 cDNA sequence reported here has been deposited in GenBank (Accession number AF173994).
